Chengdu huasun technology group Inc (000790) Fair Value & Analysis
Healthcare · CN · Market cap 2.3B CNY
Fair value as of: Jun 25, 2026
Analysis
Chengdu huasun technology group Inc (000790) currently trades at ¥3.67, while our model-based Fair Value estimate is ¥5.16 — implying the stock looks roughly 40.6% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Chengdu huasun technology group Inc. , LTD. manufactures and sells medicines, bio-pharmaceutical products, and building steel structures. The company manufactures modern Chinese medicines, Chinese patent medicines, chemical medicines, and drugs. It also engages in the research and development, production, and sale of biological products and biotechnology drugs, as well as medicines for the treatment of cardiovascular and cerebrovascular diseases. In addition, the company designs, produces, installs, and services steel structure buildings. The company was formerly known as Chengdu Taihe Health Technology Group Inc., Ltd. and changed its name to Chengdu huasun technology group Inc. , LTD. in April 2020. The company was founded in 1988 and is based in Chengdu, China.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Chengdu huasun technology group Inc (000790) undervalued?
What is the fair value of 000790?
What is the quality score of 000790?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.